A Phase II trial of guadecitabine (G) plus atezolizumab (A) in patients with metastatic urothelial carcinoma (UC) progressing after initial checkpoint inhibitor therapy.

被引：0
|
作者：
Plimack, Elizabeth R. [1 ]
Campbell, Kerry [1 ]
Issa, Jean-Pierre J. [2 ]
Hahn, Noah M. [3 ]
Quinn, David I. [4 ]
Jang, Hyo Sik [5 ]
Hostetter, Galen [5 ]
Nichols, Peter W. [4 ]
Chung, Woonbok [2 ]
Madzo, Jozef [2 ]
Ohtani, Hitoshi [5 ]
Shen, Hui [5 ]
Hinoue, Toshinori [5 ]
Baylin, Stephen B. [3 ]
Jones, Peter A. [5 ]
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Coriell Inst Med Res, Camden, NJ USA
[3] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Van Andel Res Inst, Grand Rapids, MI USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT121
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma
    Shuichiro Iwasaki
    Hisashi Hidaka
    Haruki Uojima
    Miho Hashimura
    Takeru Nabeta
    Itaru Sanoyama
    Naohisa Wada
    Kousuke Kubota
    Takahide Nakazawa
    Akitaka Shibuya
    Wasaburo Koizumi
    Clinical Journal of Gastroenterology, 2021, 14 : 1233 - 1239
  • [32] A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma
    Iwasaki, Shuichiro
    Hidaka, Hisashi
    Uojima, Haruki
    Hashimura, Miho
    Nabeta, Takeru
    Sanoyama, Itaru
    Wada, Naohisa
    Kubota, Kousuke
    Nakazawa, Takahide
    Shibuya, Akitaka
    Koizumi, Wasaburo
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2021, 14 (04) : 1233 - 1239
  • [33] AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
    Carlotta Antoniotti
    Beatrice Borelli
    Daniele Rossini
    Filippo Pietrantonio
    Federica Morano
    Lisa Salvatore
    Sara Lonardi
    Federica Marmorino
    Stefano Tamberi
    Salvatore Corallo
    Giampaolo Tortora
    Francesca Bergamo
    Di Stefano Brunella
    Alessandra Boccaccino
    Elisa Grassi
    Patrizia Racca
    Emiliano Tamburini
    Giuseppe Aprile
    Roberto Moretto
    Luca Boni
    Alfredo Falcone
    Chiara Cremolini
    BMC Cancer, 20
  • [34] A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma
    Hidaka, Hisashi
    Kamata, Hirotoshi
    Uojima, Haruki
    Iwasaki, Shuichiro
    Iida, Junki
    Nakazawa, Takahide
    Kusano, Chika
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (06) : 1075 - 1079
  • [35] AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
    Antoniotti, Carlotta
    Borelli, Beatrice
    Rossini, Daniele
    Pietrantonio, Filippo
    Morano, Federica
    Salvatore, Lisa
    Lonardi, Sara
    Marmorino, Federica
    Tamberi, Stefano
    Corallo, Salvatore
    Tortora, Giampaolo
    Bergamo, Francesca
    Brunella, Di Stefano
    Boccaccino, Alessandra
    Grassi, Elisa
    Racca, Patrizia
    Tamburini, Emiliano
    Aprile, Giuseppe
    Moretto, Roberto
    Boni, Luca
    Falcone, Alfredo
    Cremolini, Chiara
    BMC CANCER, 2020, 20 (01)
  • [36] Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma or renal cell carcinoma
    Maia, Manuel Caitano
    Agarwal, Neeraj
    McGregor, Bradley
    Vaishampayan, Ulka
    Choueiri, Toni K.
    Green, Marjorie
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Powles, Thomas
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [37] Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma
    Gartrell, Benjamin Adam
    Hahn, Noah M.
    Hutson, Thomas E.
    Sonpavde, Guru
    Hauke, Ralph J.
    Starodub, Alexander
    Small, Alexander C.
    Tsao, Che-Kai
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Phase II trial of gemcitabine plus carboplatin for urothelial transitional cell carcinoma (UTCC) in advanced or metastatic stage
    Santoro, A
    Santoro, M
    Maiorino, L
    Forestieri, V
    Forestieri, P
    ANNALS OF ONCOLOGY, 1998, 9 : 169 - 169
  • [39] TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
    Tagawa, Scott T.
    Balar, Arjun, V
    Petrylak, Daniel P.
    Kalebasty, Arash Rezazadeh
    Loriot, Yohann
    Flechon, Aude
    Jain, Rohit K.
    Agarwal, Neeraj
    Bupathi, Manojkumar
    Barthelemy, Philippe
    Beuzeboc, Philippe
    Palmbos, Phillip
    Kyriakopoulos, Christos E.
    Pouessel, Damien
    Sternberg, Cora N.
    Hong, Quan
    Goswami, Trishna
    Itri, Loretta M.
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) : 2474 - +
  • [40] Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
    Giannatempo, P.
    Polymeropoulos, A.
    Stellato, M.
    Ambrosini, P.
    Gusmaroli, E.
    Cavalli, C.
    Guadalupi, V.
    Claps, M.
    Raggi, D.
    Rametta, A.
    Ortega, C.
    Tucci, M.
    Buti, S.
    Pipitone, S.
    Iacovelli, R.
    Calareso, G.
    Alessi, A.
    Procopio, G.
    Miceli, R.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1161 - S1161
12345